Enodia Therapeutics
0 followers
About Enodia Therapeutics
Enodia Therapeutics is a biotechnology company developing small-molecule therapies that selectively degrade disease-driving proteins by targeting the Sec61 translocon, acting at the start of protein synthesis. The approach aims to degrade pathogenic proteins upstream while preserving essential secretion, with lead programs focused on immuno-inflammatory diseases and potential applications in oncology. The company originated from scientific work at Institut Pasteur and is developed with Argobio Studio, supported by investors to advance best-in-class therapies.